A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplantation CMVIG-Study Group

Transplant Proc. 1994 Oct;26(5 Suppl 1):23-7.

Authors

D R Snydman¹, B G Werner, N N Dougherty, J Griffith, R H Rohrer, R Freeman, R Jenkins, W D Lewis, E O'Rourke

Affiliation

¹ Department of Medicine, New England Medical Center, Boston, MA 02111.

PMID: 7940972

No abstract available

Publication types

Clinical Trial
Multicenter Study
Randomized Controlled Trial

MeSH terms

Acyclovir / therapeutic use
Adult
Boston
Candidiasis / etiology
Child
Cytomegalovirus / immunology*
Cytomegalovirus / isolation & purification
Cytomegalovirus Infections / prevention & control*
Female
Ganciclovir / therapeutic use
Humans
Immunization, Passive*
Immunoglobulins / therapeutic use*
Immunoglobulins, Intravenous
Immunosuppressive Agents / therapeutic use
Liver Transplantation*
Male
Muromonab-CD3 / therapeutic use
Opportunistic Infections / etiology
Placebos
Pneumonia, Viral / etiology
Risk Factors
Treatment Outcome

Substances

Immunoglobulins
Immunoglobulins, Intravenous
Immunosuppressive Agents
Muromonab-CD3
Placebos
cytomegalovirus-specific hyperimmune globulin
Ganciclovir
Acyclovir